Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry-based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.

Employees

261

Sector

Real Estate Development & Operations

More about the company

Quotes

Date	Price	Change	Volume
21/10/26	₹92.00	-3.31%	37,898
19/10/26	₹95.15	-2.26%	37,908
16/10/26	₹97.35	+1.09%	64,774
15/10/26	₹96.30	-2.18%	57,045
14/10/26	₹98.45	+0.20%	35,594

Delayed Quote Bombay S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Bombay S.E. 11:02:26 21/10/2026 BST			5-day change	1st Jan Change
92.00 ^INR	-3.31%		-6.36%	-8.96%

09-21	Alembic Limited(BSE:506235) dropped from S&P Global BMI Index	CI
08-11	Alembic Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

Market Cap	23.62B 250M 223M 207M 187M 352M 356M 2.48B 972M 12.42B 939M 920M 39.57B	P/E 2025	8.14x	P/E 2026	5.74x
Enterprise Value	22.75B 241M 215M 199M 180M 339M 343M 2.38B 936M 11.96B 904M 886M 38.11B	EV / Sales 2025	11.2x	EV / Sales 2026	7.22x
Free-Float	27.23%	Yield 2025	2.44%	Yield 2026	3.38%

Markets		Quality
Bombay S.E.	ALEMBICLTD	Delayed
NSE India S.E.	ALEMBICLTD	Delayed

09-21	Alembic Limited(BSE:506235) dropped from S&P Global BMI Index	CI
08-11	Alembic Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
05-19	Alembic Limited Recommends Dividend for the Year Ended March 31, 2026	CI
05-19	Alembic Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
04-23	Alembic Pharmaceuticals Incorporates Philippines Subsidiary	MT
02-12	Alembic Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
11-27	Bajaj Healthcare Limited Appoints Shreekumar Shankarnarayan Nair as Chief Operating Officer, Effective November 27, 2025	CI
11-17	Accenture Invests in AI Marketing Intelligence Platform Alembic	MT
11-17	Alert wrongly tagged to India's Alembic withdrawn	RE
11-17	Alembic raises $145 million to accelerate enterprise adoption of causal AI	RE
11-17	Accenture invests in Alembic to reinvent marketing measurement with data and Causal AI	RE
11-10	Alembic Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
12/08/25	Alembic Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI

Alembic Limited Share Price

Stocks

ALEMBICLTD

INE426A01027

Real Estate Development & Operations

Valuation: Alembic Limited

Chart: Alembic Limited

Latest news: Alembic Limited

Press Releases: Alembic Limited

Quotes and Performance

Price Extremes

Managers and Directors: Alembic Limited

Other Real Estate Development & Operations

Financials

Company Profile

Quotes

04/07/25	Alembic : Annual Report 2024-25	PU
27/05/25	Supreme Court Rules Against Ex-Post Facto Environment Clearance	AQ
14/08/24	Alembic Pharmaceuticals announces USFDA Dabigatran Etexilate Capsules, 110 mg	AQ
25/07/24	Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg	AQ
07/08/23	Alembic Pharmaceuticals - Revenue up 18% to Rs. 1486 crores in Q-1 FY24	AQ

1 day	-3.31%
1 week	-6.36%
Current month	-14.24%
1 month	-10.43%
3 months	+2.02%
6 months	+1.83%
Current year	-8.96%

1 week	91.45	99.95
1 month	91.45	112.16
Current year	70.64	117.91
1 year	70.64	117.91
3 years	70.64	169
5 years	55.52	169
10 years	25	169

Manager	Title	Age	Since
Udit Chirayu Amin CEO	Chief Executive Officer	46	30/09/2025
Rasesh J. Shah DFI	Director of Finance/CFO	-	12/08/2014
Kevalkumar B. Thakkar CMP	Compliance Officer	-	31/08/2023

Director	Title	Age	Since
Chirayu Ramanbhai Amin CHM	Chairman	78	20/08/1967
Malika Chirayu Amin BRD	Director/Board Member	71	01/07/1988
Udit Chirayu Amin BRD	Director/Board Member	46	23/04/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALEMBIC LIMITED	-3.31%	-6.36%	-9.30%	+8.11%	258M
VINGROUP	+6.99%	+0.72%	+129.45%	+931.60%	60.57B
SUN HUNG KAI PROPERTIES LIMITED	+1.13%	-2.10%	+13.47%	+31.78%	39.21B
MITSUBISHI ESTATE CO., LTD.	+2.90%	+10.52%	+13.96%	+96.27%	28.36B
CHINA RESOURCES LAND LIMITED	-0.46%	-0.98%	+2.02%	+2.34%	27.6B
EMAAR PROPERTIES	+0.35%	+1.95%	-16.82%	+80.56%	27.62B
MITSUI FUDOSAN CO., LTD.	+0.78%	+6.92%	-5.85%	+40.88%	26.09B
CK ASSET HOLDINGS LIMITED	+0.09%	-0.27%	+19.45%	+14.85%	20.08B
VINHOMES	+6.92%	-4.04%	+14.44%	+177.75%	18.35B
ALPHA DHABI HOLDING	-0.43%	-2.92%	-32.23%	-60.39%	19.07B
Average	+1.50%	+1.18%	+12.86%	+132.38%	26.72B
Weighted average by Cap.	+2.57%	+1.73%	+30.84%	+247.63%

	2025	2026
Net sales	2.22B 23.51M 20.95M 19.4M 17.56M 33.07M 33.47M 233M 91.26M 1.17B 88.21M 86.37M 3.72B	2.4B 25.43M 22.66M 20.98M 18.99M 35.77M 36.2M 252M 98.71M 1.26B 95.4M 93.42M 4.02B
Net income	3.11B 32.92M 29.34M 27.16M 24.58M 46.31M 46.86M 326M 128M 1.63B 124M 121M 5.2B	3.17B 33.63M 29.97M 27.75M 25.11M 47.31M 47.87M 333M 131M 1.67B 126M 124M 5.32B
Net Debt	-438M -4.64M -4.14M -3.83M -3.47M -6.53M -6.61M -45.94M -18.02M -230M -17.42M -17.06M -734M	-874M -9.26M -8.25M -7.64M -6.91M -13.03M -13.18M -91.61M -35.95M -459M -34.74M -34.02M -1.46B